Sun Pharmaceutical’s June quarter results were weighed down by weak sales in the US market, especially in the high-margin specialty segment. Its American sales slid 24.6 per cent on a sequential basis, as Sun’s specialty portfolio, as well as its subsidiary Taro Pharma’s sales, dipped 33-38 per cent.
Taro Pharma, which accounted for 42 per cent of Sun’s US sales, reported its worst quarterly performance in nine years. The derma (skin) product segment, which accounts for around two-thirds of Taro’s sales, was the worst-affected due to pricing pressures. ...
TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST Rs
Key stories on business-standard.com are available to premium subscribers only.
Already a premium subscriber? LOGIN NOW
Copyrights © 2020 Business Standard Private Ltd. All rights reserved.
